Although the majority of the patients with advanced ovarian cancer will die of the disease,
optimism is justified in view of the improved results of surgery followed by cisplatin-and …

Objectives: To investigate the effects of angiogenesis inhibitors in the treatment of patients
with advanced or recurrent ovarian cancer, a meta-analysis was performed and overall …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Background/Aim: We aimed to identify the most effectual groups of targeted therapies for
ovarian cancer in recent clinical trials. Materials and Methods: A systematic literature review …

Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in
the front-line therapy of advanced epithelial ovarian cancer during the last decade …

Effective and well tolerated treatment for platinum-resistant ovarian cancer remains a
substantial unmet need. Despite the introduction of targeted and immunological therapies …

Ovarian cancer affects 23,400 women in the United States annually and is responsible for
13,900 deaths.[1] It is the fifth most common cause of cancer deaths among women in the …

Despite advances in surgery and chemotherapy, less than 20% of patients with stage III or IV
ovarian cancer survive long-term. In the past, cytotoxic regimens have been developed …

Ovarian cancer leads to more fatalities than any other form of gynaecological cancer in
North America and Europe. Over the last 30 years survival figures have improved somewhat …

The process of angiogenesis is well described for its potential role in the development of
normal ovaries, and physiological functions as well as in the initiation, progression, and …